Emyria Ltd
ASX:EMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Emyria Ltd
ASX:EMD
|
AU |
|
Anglogold Ashanti PLC
F:HT3
|
UK |
|
Jammu and Kashmir Bank Ltd
NSE:J&KBANK
|
IN |
|
R
|
Rekatech Capital Bhd
KLSE:REKATECH
|
MY |
|
HCL Technologies Ltd
NSE:HCLTECH
|
IN |
|
Intel Corp
NASDAQ:INTC
|
US |
|
T
|
Tongyang Pile Inc
KOSDAQ:228340
|
KR |
|
D
|
Dimeco Inc
OTC:DIMC
|
US |
|
N
|
Nanjing Securities Co Ltd
SSE:601990
|
CN |
|
Z
|
Zhongfu Shenying Carbon Fiber Co Ltd
SSE:688295
|
CN |
|
International Petroleum Corp
STO:IPCO
|
CA |
|
Bourse Direct SA
F:BD6
|
FR |
|
C
|
CK Power PCL
SET:CKP
|
TH |
|
N
|
Nanyang Holdings Ltd
HKEX:212
|
HK |
|
NHK Spring Co Ltd
TSE:5991
|
JP |
|
Park Aerospace Corp
NYSE:PKE
|
US |
|
S
|
Synergetic Auto Performance PCL
SET:ASAP
|
TH |
Emyria Ltd
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
